Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Tibet Duo Rui Pharmaceutical
301075
5
Chengda Pharmaceuticals
301201
(Q3)Jan 31, 2025 | (Q2)Oct 31, 2024 | (Q1)Jul 31, 2024 | (FY)Apr 30, 2024 | (Q4)Apr 30, 2024 | (Q3)Jan 31, 2024 | (Q2)Oct 31, 2023 | (Q1)Jul 31, 2023 | (FY)Apr 30, 2023 | (Q4)Apr 30, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow (Indirect Method) | ||||||||||
Cash flow from continuing operating activities | -96.37%41.63K | 108.24%75.37K | -127.19%-72.65K | 72.28%-3M | -232.83%-3.5M | 122.22%1.15M | 74.07%-915.25K | 105.60%267.2K | 38.19%-10.83M | 127.58%2.64M |
Net income from continuing operations | 12,547.72%9.64M | -177.53%-1.37M | -398.46%-4.22M | 78.02%-15.64M | -135.89%-16.47M | 99.84%-77.41K | 115.99%1.76M | 80.15%-846.77K | -37.43%-71.15M | 2.23%-6.98M |
Operating gains losses | --5.07K | 99.86%-4.91K | 99.99%-154 | -83.57%6.48M | ---- | ---- | -181.37%-3.4M | 41.84%-2.14M | 444.31%39.46M | -70.54%-5.94M |
Depreciation and amortization | 602.94%2.23M | --0 | --0 | -99.00%115.07K | -102.77%-317.62K | 811.05%317.62K | --0 | --115.07K | 26,443.24%11.56M | 16,291.90%11.45M |
Other non cash items | ---2.44M | --0 | 53.91%2.5M | -21.89%3.58M | ---- | ---- | --251.93K | -44.09%1.63M | -65.90%4.59M | 192.26%1.32M |
Change In working capital | -240.14%-9.39M | 206.21%1.45M | 8.46%1.65M | -38.33%2.45M | 15.53%3.22M | -55.31%-2.76M | -84.07%472.36K | --1.52M | 1,665.03%3.98M | 256.47%2.79M |
-Change in receivables | -761.04%-9.96M | 431.19%171.02K | -93.52%17.24K | 109.31%127.45K | 699.69%1.07M | 39.07%-1.16M | -113.03%-51.64K | --265.99K | -408.92%-1.37M | -19.64%133.81K |
-Change in inventory | ---442.2K | -26.15%493.85K | -106.06%-51.65K | -64.18%1.58M | ---- | ---- | -81.16%668.73K | --852.85K | 205.41%4.41M | -33.81%526.45K |
-Change in prepaid assets | ---877.74K | 118.95%922.89K | 77.28%-45.15K | -22.57%226.01K | ---- | ---- | 177.94%421.5K | ---198.75K | 134.70%291.89K | -27.48%679.37K |
-Change in payables and accrued expense | 214.20%2.5M | 54.99%-402.67K | 408.45%1.38M | -118.43%-942.36K | -259.55%-1.11M | 217.19%794.89K | -98.19%-894.55K | --271.33K | -105.35%-431.43K | -61.69%698.25K |
-Change in other current liabilities | ---- | -20.40%261.34K | 6.08%346.4K | 36.22%1.46M | ---- | ---- | 2,891.81%328.32K | --326.55K | 135.53%1.07M | 124.92%752.65K |
Cash from discontinued investing activities | 0 | -13.38%4.46M | -143.22%-2.16M | |||||||
Operating cash flow | -96.37%41.63K | 108.24%75.37K | -127.19%-72.65K | 52.85%-3M | -828.76%-3.5M | 235.61%1.15M | 25.63%-915.25K | 105.60%267.2K | 48.53%-6.37M | 110.51%480.42K |
Investing cash flow | ||||||||||
Cash flow from continuing investing activities | -16.5M | 0 | ||||||||
Net investment purchase and sale | ---- | ---- | ---- | ---16.5M | ---- | ---- | ---- | ---- | --0 | ---- |
Cash from discontinued investing activities | ||||||||||
Investing cash flow | ---- | ---- | ---- | ---16.5M | ---- | ---- | ---- | ---- | --0 | ---- |
Financing cash flow | ||||||||||
Cash flow from continuing financing activities | -105.47%-68.63K | 368.71%1.61M | 234.62%19.48M | -35.25%1.26M | -117.64%-601K | -57.62%5.82M | -118.74%-660.59K | |||
Net issuance payments of debt | ---- | -105.53%-69.45K | 99.46%-3.22K | 151.89%1.52M | ---- | ---- | 141.02%1.26M | 23.81%-601K | -120.12%-2.92M | -105.96%-210.59K |
Net common stock issuance | ---- | ---- | ---- | 105.40%17.96M | ---- | ---- | ---- | ---- | --8.74M | ---450K |
Proceeds from stock option exercised by employees | ---- | --820 | --1.62M | ---- | ---- | ---- | --0 | --0 | ---- | ---- |
Cash from discontinued financing activities | ||||||||||
Financing cash flow | ---- | -105.47%-68.63K | 368.71%1.61M | 234.62%19.48M | ---- | ---- | -35.25%1.26M | -117.64%-601K | -57.62%5.82M | -118.74%-660.59K |
Net cash flow | ||||||||||
Beginning cash position | 474.74%1.64M | 1,243.10%1.71M | 13.66%229.71K | -69.61%202.1K | 57.75%499.68K | 48.99%285.86K | 76.25%-149.71K | -69.61%202.1K | -27.40%665K | -70.03%316.75K |
Current changes in cash | -405.05%-1.5M | -98.02%6.74K | 562.04%1.54M | 95.88%-22.44K | -189.80%-522.12K | 69.89%493.26K | -51.97%340.23K | 75.50%-333.8K | -117.03%-544.2K | 56.51%-180.16K |
Effect of exchange rate changes | ---- | -178.72%-75.06K | -237.47%-60.73K | -38.43%50.05K | ---- | ---- | -16.29%95.34K | -126.72%-18K | 42,221.76%81.3K | 191.42%65.51K |
End cash Position | -83.25%83.71K | 474.74%1.64M | 1,243.10%1.71M | 13.66%229.71K | 13.66%229.71K | 57.75%499.68K | 48.99%285.86K | 76.25%-149.71K | -69.61%202.1K | -69.61%202.1K |
Free cash flow | -96.37%41.63K | 108.24%75.37K | -127.19%-72.65K | 52.85%-3M | -828.76%-3.5M | 235.61%1.15M | 25.63%-915.25K | 105.60%267.2K | 48.53%-6.37M | 110.51%480.42K |
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- |